PT  - JOURNAL ARTICLE
AU  - Yishay Pinto
AU  - Sigal Frishman
AU  - Sondra Turjeman
AU  - Adi Eshel
AU  - Meital Nuriel-Ohayon
AU  - Oren Ziv
AU  - William Walters
AU  - Julie Parsonnet
AU  - Catherine Ley
AU  - Elizabeth L. Johnson
AU  - Ron Schweitzer
AU  - Soliman Khatib
AU  - Faiga Magzal
AU  - Snait Tamir
AU  - Kinneret Tenenbaum Gavish
AU  - Samuli Rautava
AU  - Seppo Salminen
AU  - Erika Isolauri
AU  - Or Yariv
AU  - Yoav Peled
AU  - Eran Poran
AU  - Joseph Pardo
AU  - Rony Chen
AU  - Moshe Hod
AU  - Ruth E. Ley
AU  - Betty Schwartz
AU  - Eran Hadar
AU  - Yoram Louzoun
AU  - Omry Koren
TI  - First trimester gut microbiome induces Inflammation-dependent gestational diabetes phenotype in mice
AID  - 10.1101/2021.09.17.21262268
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.17.21262268
4099  - http://medrxiv.org/content/early/2021/09/27/2021.09.17.21262268.short
4100  - http://medrxiv.org/content/early/2021/09/27/2021.09.17.21262268.full
AB  - Gestational diabetes mellitus (GDM) is a condition in which non-diabetic women are diagnosed with glucose intolerance during pregnancy, typically in the second trimester. GDM can lead to a wide range of obstetrical and metabolic complications for both mother and neonate1. Early identification of GDM risk, along with a better understanding of its pathophysiology during the first trimester of pregnancy, may be effective in reducing GDM incidence, as well as its associated short and long term morbidities2. Here, we comprehensively profiled the gut microbiome, metabolome, inflammatory cytokines, nutrition and clinical records of 394 women during the first trimester of pregnancy. We found elevated levels of proinflammatory serum cytokines in those who later developed GDM. The women’s stool samples were also characterized by decreased levels of several fecal short-chain fatty acids and altered microbiome. We next tested the hypothesis that differences in GDM-associated microbial composition during the first trimester drove inflammation and insulin-resistance. Stool samples collected early in pregnancy from women from three populations who did and did not later develop GDM were transplanted to germ-free mice and confirmed that both inflammation and insulin-resistance are induced by the microbiome of pregnant women more than 10 weeks prior to GDM diagnosis. Following these observations, we used a machine-learning approach to predict GDM based on first trimester clinical, microbial and inflammatory markers. Our model showed high predictive accuracy. Overall, our results suggest that the gut microbiome of women in the first trimester plays a remarkable role in inflammation-induced GDM pathogenesis and point to dozens of GDM markers during the first trimester of pregnancy, some of which may be targets for therapeutic intervention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02649374Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Data and samples for this study were collected from women with informed consent in accordance with Clalit institutional review board, under ethics approval number 0135-15-COM or in accordance with Rabin Medical Center institutional review board, under ethics approval number 0263-15-RMC. In addition, fecal samples and GDM status were collected from women following informed consent as part of the STORK cohort (study approved by the Institutional Review Boards of Stanford University and the Santa Clara Valley Medical Center, trial registration number NCT01442701) and a Finnish cohort (study protocol approved by the Ethics Committee of the Hospital District of South-West Finland, trial registration number NCT00167700) for use in the FMT mouse model studies. Participant identifiers are anonymized and data in the manuscript are presented without patient identifiers or a group averages. Animal All animal experimental procedures were reviewed and approved by the Institutional Animal Care and Usage Committee of Cornell University, protocol number 2010-0065, and by the Institutional Animal Care and Usage Committee of Bar-Ilan University, protocol number 33-04-2018.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made public once the paper is accepted